• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities.

作者信息

Salerno Sara N, Burckart Gilbert J, Huang Shiew-Mei, Gonzalez Daniel

机构信息

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

出版信息

Clin Pharmacol Ther. 2019 May;105(5):1067-1070. doi: 10.1002/cpt.1234. Epub 2018 Oct 25.

DOI:10.1002/cpt.1234
PMID:30362111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6465091/
Abstract
摘要

相似文献

1
Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities.儿科药物相互作用研究：障碍与机遇
Clin Pharmacol Ther. 2019 May;105(5):1067-1070. doi: 10.1002/cpt.1234. Epub 2018 Oct 25.
2
2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.2017 年 ACC/AAP/AHA 关于儿科药物研发机遇与挑战的健康政策声明：从西地那非中吸取经验教训。
J Am Coll Cardiol. 2017 Jul 25;70(4):495-503. doi: 10.1016/j.jacc.2017.04.007. Epub 2017 Jun 29.
3
Counting the Ways to Count Medications: The Challenges of Defining Pediatric Polypharmacy.细数用药计数方式：定义儿科多重用药的挑战。
J Hosp Med. 2019 Aug;14(8):506-507. doi: 10.12788/jhm.3213.
4
Medicine Safety Monitoring in Pediatric Population in India.印度儿科人群的药物安全监测
Indian J Pediatr. 2016 May;83(5):479-80. doi: 10.1007/s12098-015-1931-z. Epub 2015 Dec 4.
5
The safety of inpatient pediatrics: preventing medical errors and injuries among hospitalized children.住院儿科的安全：预防住院儿童的医疗差错和伤害。
Pediatr Clin North Am. 2005 Aug;52(4):979-93, vii. doi: 10.1016/j.pcl.2005.05.001.
6
Risk analysis in pediatric inpatients.儿科住院患者的风险分析。
Arch Pediatr. 2018 Oct;25(7):405-410. doi: 10.1016/j.arcped.2018.08.005. Epub 2018 Sep 21.
7
Considerations for neonatal and pediatric pain management.新生儿和儿科疼痛管理的注意事项。
Am J Health Syst Pharm. 2019 Sep 16;76(19):1511-1520. doi: 10.1093/ajhp/zxz166.
8
Time to change the paradigm of children's medicines from liquid formulations to flexible solid oral dosage forms.是时候将儿童药物的剂型模式从液体制剂转变为灵活的固体口服剂型了。
Ceylon Med J. 2016;61(3):93-95. doi: 10.4038/cmj.v61i3.8340.
9
What Can Mathematics Do for Drug Development?数学在药物研发中能发挥什么作用？
Bull Math Biol. 2019 Sep;81(9):3421-3424. doi: 10.1007/s11538-019-00632-x.
10
Historical development of pediatric pharmacology.儿科药理学的历史发展。
Handb Exp Pharmacol. 2011;205:v-vi.

引用本文的文献

1
PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric Populations.支持儿科人群生物利用度和生物等效性评估的生理药代动力学（PBPK）建模
Pharm Res. 2025 Mar 26. doi: 10.1007/s11095-025-03846-y.
2
Drug-Drug Interactions Involving High-Alert Medications that Lead to Interaction-Associated Symptoms in Pediatric Intensive Care Patients: A Retrospective Study.药物-药物相互作用涉及高警示药物，可导致儿科重症监护病房患者出现与相互作用相关的症状：一项回顾性研究。
Paediatr Drugs. 2024 Sep;26(5):619-629. doi: 10.1007/s40272-024-00641-x. Epub 2024 Jul 4.
3
Membrane transporters in drug development and as determinants of precision medicine.

本文引用的文献

1
Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children.泊沙康唑在婴儿和儿童中的临床药代动力学和剂量推荐。
Clin Pharmacokinet. 2019 Jan;58(1):53-61. doi: 10.1007/s40262-018-0658-1.
2
Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.儿科药物开发中的药代动力学-药效学建模，以及标准化清除率缩放的重要性。
Clin Pharmacokinet. 2019 Jan;58(1):39-52. doi: 10.1007/s40262-018-0659-0.
3
Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition.
药物开发中的膜转运体和精准医学的决定因素。
Nat Rev Drug Discov. 2024 Apr;23(4):255-280. doi: 10.1038/s41573-023-00877-1. Epub 2024 Jan 24.
4
Major Drug-Drug Interaction Exposure Among Medicaid-Insured Children in the Outpatient Setting.门诊环境下享受医疗补助保险的儿童中主要药物-药物相互作用的暴露情况。
Pediatrics. 2024 Jan 1;153(2). doi: 10.1542/peds.2023-063506.
5
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations.儿科生理基于药代动力学模型在学术和行业组织中的应用不断增加。
CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):373-383. doi: 10.1002/psp4.12764. Epub 2022 Feb 17.
6
Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.基于模型的药物-药物相互作用外推策略：利司扑兰在患有脊髓性肌萎缩症的儿科患者中的应用。
Clin Pharmacol Ther. 2021 Dec;110(6):1547-1557. doi: 10.1002/cpt.2384. Epub 2021 Sep 1.
7
Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations.儿科药物-药物相互作用评估：药物、患者人群和方法学考虑因素。
J Clin Pharmacol. 2021 Jun;61 Suppl 1(Suppl 1):S175-S187. doi: 10.1002/jcph.1881.
8
Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.美罗培南在早产儿和足月儿体内的生理药代动力学模型研究。
Clin Pharmacokinet. 2021 Dec;60(12):1591-1604. doi: 10.1007/s40262-021-01046-6. Epub 2021 Jun 22.
9
A whole of population retrospective observational study on the rates of polypharmacy in New Zealand 2014 to 2018 Polypharmacy in New Zealand: What is the current status?一项关于2014年至2018年新西兰多重用药率的全人群回顾性观察研究 新西兰的多重用药情况：现状如何？
Health Sci Rep. 2021 Mar 10;4(2):e263. doi: 10.1002/hsr2.263. eCollection 2021 Jun.
10
Supportive care medications coinciding with chemotherapy among children with hematologic malignancy.支持性护理药物与血液恶性肿瘤患儿的化疗同时使用。
Leuk Lymphoma. 2020 Aug;61(8):1920-1931. doi: 10.1080/10428194.2020.1749604. Epub 2020 Apr 7.
头孢曲松和甲硝唑在严重急性营养不良儿童中的剂量。
Clin Pharmacol Ther. 2018 Dec;104(6):1165-1174. doi: 10.1002/cpt.1078. Epub 2018 Apr 19.
4
Predicting CD4 T-Cell Reconstitution Following Pediatric Hematopoietic Stem Cell Transplantation.预测儿童造血干细胞移植后的CD4 T细胞重建
Clin Pharmacol Ther. 2017 Aug;102(2):349-357. doi: 10.1002/cpt.621. Epub 2017 May 26.
5
Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals.美国儿童医院重症监护病房儿科患者多重用药及潜在药物相互作用的流行病学
Pediatr Crit Care Med. 2016 May;17(5):e218-28. doi: 10.1097/PCC.0000000000000684.
6
Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals.儿童医院婴幼儿及青少年患者的潜在药物-药物相互作用。
Pediatrics. 2015 Jan;135(1):e99-108. doi: 10.1542/peds.2014-2015. Epub 2014 Dec 15.
7
An adaptive design to investigate the effect of ketoconazole on pharmacokinetics of GSK239512 in healthy male volunteers.一项用于研究酮康唑对健康男性志愿者体内GSK239512药代动力学影响的适应性设计。
J Clin Pharmacol. 2015 May;55(5):505-11. doi: 10.1002/jcph.441. Epub 2015 Feb 4.
8
Do children have the same vulnerability to metabolic drug–drug interactions as adults? A critical analysis of the literature.儿童是否与成人一样容易受到代谢性药物-药物相互作用的影响？文献批判性分析。
J Clin Pharmacol. 2013 May;53(5):559-66. doi: 10.1002/jcph.13.
9
Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions.年龄相关的药物分数消除途径变化：评估可变个体发育对代谢性药物相互作用的影响。
J Clin Pharmacol. 2013 Aug;53(8):857-65. doi: 10.1002/jcph.100. Epub 2013 May 30.